SHR-1918 for high cholesterol not controlled by statins plus PCSK9 inhibitors

Trial details

Who runs it

Beijing Suncadia Pharmaceuticals Co., Ltd

Trial code

NCT07404553

Record updated

16 June 2026

Original description

The purpose of the study is to evaluate the efficacy and safety of SHR-1918 in patients with hypercholesterolemia with inadequate lipid control on statins plus PCSK9 inhibitors. The efficacy and safety of SHR-1918 will be evaluated after 12-weeks and 24-weeks treatment.Read full original descriptionShow less

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II/III Study to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 Inhibitors

The purpose of the study is to evaluate the efficacy and safety of SHR-1918 in patients with hypercholesterolemia with inadequate lipid control on statins plus PCSK9 inhibitors. The efficacy and safety of SHR-1918 will be evaluated after 12-weeks and 24-weeks treatment.

Inclusion: Male and female ≥ 18 years old and ≤ 85 years old, who is able and willing to provide a written informed consent; TG ≤ 5.6 mmol/L; LDL-C ≥ 2.6 mmol/L for moderate to high ASCVD risk, LDL-C ≥ 1.8 mmol/L for very high ASCVD risk, LDL-C ≥ 1.4 mmol/L for ultra-high ASCVD risk; Male and female subjects of childbearing potential and their partners must have no plans to donate sperm or become pregnant during the entire study period and after the last dose, and agree to use contraceptive methods as specified in the protocol.

Exclusion: Heart failure with New York Heart Association (NYHA) Class III-IV prior to screening or randomization; Acute ischemic ASCVD events within 3 months prior to screening or randomization; Have severe cardiac arrhythmia within 3 months prior to screening or randomization; History of percutaneous coronary intervention, history of coronary artery bypass grafting (CABG), history of peripheral arterial revascularisation within 1 month prior to screening or randomization; Poorly controlled type 2 diabetes mellitus or previously diagnosed type 1 diabetes mellitus; poorly controlled hypertension; Received plasma exchange therapy within 2 months prior to screening, or plans to receive plasma exchange therapy during the study period, or has received LDL receptor gene therapy prior to screening; Have a history of major surgery within 3 months prior to screening, or plans to undergo major surgery during the study period; Participated in or is participating in other clinical studies and has received study interventions within the past month prior to screening; History of severe allergies/hypersensitivity reactions, or clinically significant allergies/hypersensitivity reactions as judged by the investigator, or history of allergies to drugs with similar chemical structures; Have a history of diseases that significantly affect blood lipid levels, such as nephrotic syndrome, severe liver diseases, Cushing's syndrome, or have severe arrhythmia prior to screening or randomization; Malignant tumors within 5 years; It's planned to research transcutaneous coronary intervention, coronary artery bypass grafting, carotid or peripheral artery reconstruction, pacemaker implantation, cardiac resynchronisation therapy (CRT), implantable cardioverter defibrillator (ICD) implantation and other implantations during the study; History of drug use, substance abuse, and alcohol abuse; Echocardiography indicates a left ventricular ejection fraction (LVEF) of less than 30% within 3 months prior to screening; Researchers determine that the subject has poor compliance or any factors that make them unsuitable for participation in this trial, including but not limited to participation in the study placing the subject at unacceptable risk or potentially interfering with the study results.

ClinicalTrials.gov NCT07404553